Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies

Liping Dou, MDa, Lu Wang, MMa, Xin Li, MMb, Yvchen Liu, BDa, Fei Li, MMa, Lijun Wang, MDa, Xiaoning Gao, MDa, Wenrong Huang, MDa, Shuhong Wang, MDa, Chunji Gao, MMb, Li Yu, MDa, Dailong Liu, MDa,∗

Abstract

Background: High incidence of chronic graft-versus-host disease (GVHD) has been a major drawback of matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT). This study aimed to investigate the safety and efficacy of antithymocyte globulin (ATG) as a standardized part of GVHD prophylaxis in patients receiving MSD-PBSCT.

Methods: A total of 72 patients with hematologic malignancies receiving MSD-PBSCT who displayed similar baseline characteristics were either given rabbit ATG (n = 42) or no ATG (n = 30), in addition to cyclosporine, methotrexate, and mycophenolate mofetil as a standard GVHD prophylaxis regimen. Either patients or donors aged ≥40 years were included in the study. Thymoglobulin was administered at a daily dose of 1.5 mg/kg on days −5 and 3.5 mg/kg on day −4 prior to transplant (the total dose was 5 mg/kg).

Results: After a median follow-up of 874 days, the 3-year cumulative incidence of chronic GVHD (cGVHD) was 37.3% in the ATG group and 52.1% in the non-ATG group. The 3-year overall and disease-free survival probability were 71.0% and 62.0% (ATG versus non-ATG, P = .262) and 66.7% and 58.4% (ATG versus non-ATG, P = .334). No difference was found in the 2-year cumulative incidence of nonrelapse mortality and relapse between the ATG and non-ATG groups. This significant reduction in the incidence of cGVHD without increased relapse risk and nonrelapse mortality led to a 3-year GVHD-free, relapse-free survival probability of 66.7% and 40.0% in the ATG and non-ATG groups, respectively.

Conclusions: These data suggested that rabbit antithymocyte globulin in the current protocol for GVHD prophylaxis was well tolerable and efficacious.

The clinical trial was registered on January 1, 2016 (ClinicalTrials.gov Identifier NCT02677181). https://clinicaltrials.gov/ct2/show/NCT02677181.

Abbreviations: GVHD = graft-versus-host disease, MSD-PBSCT = matched sibling donor peripheral blood stem cell transplantation, rATG = rabbit antithymocyte globulin.

Keywords: ATG, graft-versus-host disease, peripheral blood, relapse, stem cell transplantation
1. Introduction

The use of in vivo T-cell depletion with rabbit antithymocyte globulin (rATG) is a promising strategy for graft-versus-host disease (GVHD) prophylaxis. However, side effects such as viral reactivation and disease relapse may increase non-relapse mortality (NRM). The administration of an appropriate regimen of rATG is critical for effective GVHD prevention. Lower rATG exposure might lead to a higher risk of GVHD while higher rATG exposure and excessive T-cell depletion can result in delayed immune reconstitution with increased risk of infections, disease relapse, and higher non-relapse mortality. As the half-life of antithymocyte globulin (ATG) is 5–14 days, the timing of ATG administration such as day –9 or day –5, also affects the outcome. High level of rATG before stem cell infusion contributed to low incidence of cGVHD and graft failure. Level of rATG after graft infusion may have impact on cGVHD, infection and early immune recovery.

The optimal dosage of ATG and its timing of treatment have not been defined, especially in matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT). Moreover, distinct brands of ATG products differ in effects on outcomes because of their manufacturing process, including the animal source and the cell line used for immunization. Anti-human thymocyte globulin was produced in rabbits (rATG, Sanofi, Paris, France) against human thymocytes, and anti-T-lymphocyte globulin (ATLG, rabbit, Fresenius, Germany) was produced by immunizing rabbits with a Jurkat cell line. Kroger et al. found that a low dose of ATLG, given at 10 mg/kg on days 3, 2, and 1 before myeloablative allogeneic PBSCT from a human leukocyte antigen (HLA)-identical donor for patients with acute leukemia in remission, decreased the risk of chronic GVHD (cGVHD), but did not improve the overall survival (OS) and relapse-free survival. We have reported that rATG of 10 mg/kg might reduce cGVHD in patients receiving haploidentical PBSCT without in vitro T-cell depletion. The incidence of extensive cGVHD was 17.1%, in patients receiving haploidentical PBSCT in our center. The ATG regimen was given at a total dose of 10 mg/kg (day –5 to –2) before graft infusion. The non-relapse mortality and relapse were acceptable in the haploidentical PBSCT setting. The incidence of acute GVHD (aGVHD) grades II–IV was high in patients receiving stem cells from donors aged ≥40 years. With thymoglobulin doses <6 mg/kg, it was reported that incidence of relapse did not increase. Therefore, we proposed that 5 mg/kg of rATG may be efficacious and tolerable in the MSD setting.

In the prospective study (ClinicalTrials.gov Identifier: NCT026777181), rATG was used for GVHD prophylaxis. The present study aimed to evaluate the impact of 5 mg/kg rATG (the total dose 5 mg/kg and the timing as days –5 and –4 before graft infusion), in patients or donors aged ≥40 years receiving matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT) on cGVHD, compared with no rATG in patients or donors aged ≥40 years, and also evaluated the tolerability and efficacy of this prophylactic strategy.

2. Methods

This study was approved by the Ethics Committee of the Chinese People’s Liberation Army General Hospital and conducted in accordance with the principles of the Declaration of Helsinki. All patients signed informed consent.

2.1. Study design

Consecutive patients with non-Hodgkin lymphoma (NHL) /acute leukemia (AML/ALL)/myelodysplastic syndrome (MDS) who received allogeneic MSD-PBSCT at the study center from August 1, 2015, to December 30, 2018, were eligible.

The sample size was 128, which was estimated with PASS software (NCSS, Kaysville, UT). The sample size was calculated on the basis of the assumption that the 3-year event rate (cGVHD) in the no ATG arm was 50% according to our previous reports. This study proposed to reduce the 3-year incidence of cGVHD from 50% to 23%. Under the hypothesis, the study would have 90% power at a two-sided significance level of 0.05. This prospective, randomized, phase III study was registered as a clinical trial (ClinicalTrials.gov identifier: NCT026777181). In consideration of sample lost to follow-up, death during early treatment, and other unexpected factors, an additional 10% sample size was required; thus, the final sample size was approximately 70 patients in each group. Interim analysis would be performed after the completion of treatment of the first 60 patients in both group. If the P value for the difference of incidence of cGVHD between the two groups by fisher exact test was less than 0.0011, study termination for no ATG arm could be considered. The purpose of early termination for no ATG arm, based on significant reduction of cGVHD in ATG group for GVHD prophylaxis, was to benefit more patients. If there was a good safety profile and the P value for the difference of incidence of GVHD between the two groups was more than 0.0011, the study would be continued and the final P value cutoff should be 0.0246. The alpha splitting is based on the Lan-DeMets O’Brien-Fleming approximation spending function. If this happens, the study can drop the non –ATG arm and enroll all the rest of patients to the ATG arm. Patients were randomly assigned 1:1 between non –ATG versus ATG group. Baseline parameters were assessed before the start of conditioning regimen, Figure 1.

The inclusion criteria were as follows:
1. the age of either patients or donors was 40 to 70 years;
2. patients diagnosed with AML or MDS or NHL; and
3. indication for MSD-PBSCT.

All patients in this study received myeloablative conditioning regimens. The conditioning regimen consisted of an intravenous administration of busulfan (3.2 mg/kg per day on days –10 to –8; Otsuka Pharmaceutical Company, China), 1,3-bis(2-chloro-...
methods at HLA-A, -B, C, DP, DRB1, and DQB1. For all the donors and patients were typed by sequence-based typing.

2.2. HLA matching and graft collection

Donors and patients were typed by sequence-based typing methods at HLA-A, -B, C, DP, DRB1, and DQB1. For all the patients, the source of donor cells was granulocyte colony-stimulating factor (G-CSF)-primed peripheral stem cells alone. All donors were subcutaneously administered 5 μg/kg · day G-CSF (Filgrastim, Kirin, Japan) from day 1 to day 5 of mobilization. PBSCT was collected on day 5 of mobilization and day 6 if the target numbers for mononuclear cells did not reach above 5 x 10^6/kg or the number of CD34+ cells did not reach above 2 x 10^6/kg. The unmanipulated PBSCs alone were infused into the recipient on the day of collection.

2.3. rATG and GVHD prophylaxis

Patients in the ATG group were administered with rATG, at a daily dose of 1.5 mg/kg on day –5 and 3.5 mg/kg on day –4 prior to transplant (the total dose was 5 mg/kg).

All transplant recipients without organ dysfunction received cyclosporine A (CsA), mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. From day –10 of transplantation, CsA was given at a dose of 2 mg/kg intravenously, targeting concentration levels of 150 to 250 ng/mL during the first 3 months. After 3 months, the dose of CsA was tapered by 25% for patients without relapse every 2 weeks. Once the patients relapsed after transplantation, CsA was tapered immediately. Tacrolimus was administered in patients showing cyclosporine toxicity or intolerance. Mycophenolate mofetil at a dose of 500 mg was administered twice daily from days –10 to +14. Methotrexate at a dose of 15 mg/m² was administered on day +1, and methotrexate at a dose of 10 mg/m² was administered on days +3, +6, and +11. All patients received viral prophylaxis with ganciclovir (day –10 ~ day –2 before stem cell infusion) and acyclovir (day +1 ~ day +180 after stem cell infusion). Epstein–Barr virus (EBV) and cytomegalovirus (CMV/CMV DNA in plasma were monitored by real-time quantitative polymerase chain reaction twice weekly until 3 months after transplantation. CMV reactivation was defined as either two consecutive viral loads >1 x 10^4 copies/mL or a single viral loads >1 x 10^4 copies/mL. Pre-emptive therapy for CMV reactivation with ganciclovir lasted for at least 2 weeks until CMV DNA load decreased below 1000 copies/mL. EBV reactivation was defined as viral loads >1 x 10^3 copies/mL.

Patients who are only diagnosed as EBV DNAemia were not treated with rituximab. The treatment for EBV posttransplant lymphoproliferative disorders included administration of rituximab, chemotherapy, and EBV -specific cytotoxic lymphocyte infusion.

2.4. Immune monitoring

Recovery of immune cells after transplantation was monitored in a subset of patients on days +30, +60, +90, +180, +240, and +360. Multi-parameter flow cytometry was performed. Cell subsets characterized by CD3+, CD4+, CD8+, and CD56/CD16+ were monitored at each time point (Wilcoxon rank sum test). Recovery of immune cells were analyzed with time dependent multivariable Cox proportional hazards regression models.

2.5. Definitions and endpoints

Outcome data reported in this article were updated on December 1, 2019. The time after transplantation was recorded as “+“ days, and the time prior to transplantation was recorded as “-“ days. The primary endpoint was the incidence of cGVHD. The secondary endpoints were NRM, and relapse, GVHD-free, relapse-free survival (GRFS), incidence of aGVHD, engraftment, disease-free survival (DFS), and OS. Neutrophil engraftment was defined as absolute neutrophil count more than 0.5 x 10^9/L for 3 consecutive days, and platelet engraftment was defined as platelet count more than 20 x 10^9/L for 7 consecutive days without transfusion. Diagnoses of GVHD were defined according to published criteria. According to the National Institutes of Health (NIH) criteria, the grade of cGVHD was defined as “mild,” “moderate,” or “severe.” Relapse was defined by morphological evidence of disease in the peripheral blood, marrow, or extramedullary sites. DFS was defined as survival without disease relapse or progression. GRFS was defined as being alive with neither grade III-IV aGVHD nor moderate-to-severe cGVHD nor disease relapse at any time point.

2.6. Statistical analysis

Patient-, disease- and transplant-related characteristics were compared using the Chi-square tests or Fischer exact test for categorical variables, and the Mann–Whitney test for continuous variables. Cumulative incidence was estimated for relapse, NRM, and GVHD (grades II–IV or III–IV aGVHD and cGVHD of any severity or extensive). Competing risks were relapse or death for cGVHD or aGVHD, NRM for relapse, and relapse for NRM. The 95% confidence interval (CI) for the differences were calculated using the log-rank and Wilson score methods. OS, DFS, and GRFS were computed using the Kaplan–Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards regression analysis. The covariates were diagnosis, donor–recipient sex matching, time from diagnosis to transplantation (<6 months vs ≥6 months), status at the time of transplantation (complete remission vs others), cytogenetic risk, nucleated and CD34+ cells transplanted, blood group and compatibility, disease risk index, and the effect of ATG. All tests were two-sided and the P values < 0.05 were considered as statistically significant. Statistical analysis was conducted using the R statistical software (cmlrsk package) and SPSS 20.0.

3. Results

3.1. Patient characteristics

A total of 72 consecutive patients (32 in the non-ATG group and 40 in the ATG group) underwent stem cell transplantation and were included in this analysis (Table 1). No difference was observed in the baseline characteristics between the two groups, including the rate of disease risk according to the disease risk index. The dosage of stem cells was not different between the two groups. The median follow-up was 874 days for the whole study population, 962 days for patients alive at the last follow-up, and 391 days for those who died.
3.2. aGVHD

Among 71 patients who survived (41 in the ATG group vs 30 in the non-ATG group), 4 (6%) developed grade I aGVHD [2 (5%) in the ATG group vs 2 (7%) in the non-ATG group], 17 (24%) developed grade II aGVHD [11 (26%) in the ATG group vs 6 (20%) in the non-ATG group], 2 (3%) developed grade III aGVHD [1 (2%) vs 1 (3%)], and 1 (3%) developed grade IV aGVHD [no (0%) vs 1 (3%)], whereas 47 (65%) did not present any grade of aGVHD [27 (64%) in the ATG group vs 20 (67%) in the non-ATG group] (Table 2). No difference was found between the two groups. Using Gray’s test with competing risks, the cumulative incidence of aGVHD grades II–IV was 28.6% (95% CI, 15.8%–42.7%) in the ATG group and 26.7% (95% CI, 12.4%–43.3%) in the non-ATG group (Fig. 2A). The cumulative incidence of grades III–IV aGVHD was 2.4% (95% CI, 0.2%–11.2%) in the ATG group and 6.8% (95% CI, 1.2%–19.8%) in the non-ATG group at day +100 (Fig. 2B). The overall cumulative incidence of grades II–IV and grades III–IV aGVHD was similar between the two groups (Table 3). In the analysis of the variables affecting grades II–IV aGVHD, no risk factors were found to be associated with the occurrence of grades II–IV aGVHD. Four patients with aGVHD grades II–IV died due to disease relapse (n = 3) and pneumonia (n = 1).

Table 1
Clinical features of stem-cell transplant recipients and donors.

| Characteristic                        | ATG group | No-ATG group | P value |
|---------------------------------------|-----------|--------------|---------|
| No. of patients                       | 42        | 30           |         |
| Patient’s age, median, year (range)   | 47.6 (38–62) | 46.5 (36–63) | .184    |
| Donor’s age, median, year (range)     | 47.3 (27–59) | 46.3 (35–58) | .352    |
| Sex                                   |           |              |         |
| Male                                  | 24        | 18           |         |
| Female                                | 18        | 12           |         |
| Time between diagnosis and stem-cell transplantation, days | 180.9 (83–344) | 249.0 (38–969) | .895 |
| Diagnosis, no. (%)                    |           |              |         |
| Acute myeloid leukemia                | 21        | 14           |         |
| CR                                    | 17        | 12           |         |
| NR                                    | 4         | 2            |         |
| Acute lymphoid leukemia               | 12        | 5            |         |
| CR                                    | 12        | 5            |         |
| MDS                                    | 9         | 9            |         |
| CR                                    | 1         | 1            |         |
| Untreated                              | 8         | 8            |         |
| NH, Untreated                         | 0         | 2            |         |
| CR                                    | 0         | 2            |         |
| High cytogenetic risk, no. (%)        |           |              | .634    |
| Low                                   | 4         | 5            |         |
| Intermediate                          | 21        | 15           |         |
| High                                  | 17        | 10           |         |
| Disease risk index, no./total no. (%) |           |              | .319    |
| Low                                   | 4         | 3            |         |
| Intermediate                          | 26        | 21           |         |
| High                                  | 12        | 6            |         |
| Very high                             | 0         | 0            |         |
| Conditioning regimen                  |           |              | .317    |
| Bu/Cy                                 | 38        | 28           | .693    |
| TBI/Cy                                | 2         | 0            |         |
| Bu/Flu                                | 2         | 2            |         |
| Donor’s age, median, year (range)     | 47.3 (27–59) | 46.4 (35–58) | .317    |
| Donor–recipient ABO match             |           |              | .503    |
| Match                                 | 25        | 17           |         |
| Major mismatch                        | 7         | 8            |         |
| Minor mismatch                        | 8         | 5            |         |
| Bidirectional mismatch                 | 2         | 0            |         |
| Donor–recipient sex match             |           |              | .746    |
| Female to male                        | 15        | 8            |         |
| Female to female                      | 10        | 6            |         |
| Male to female                        | 8         | 7            |         |
| Male to male                          | 9         | 9            |         |
| Graft                                 |           |              |         |
| MNCs, median, \( \times 10^9 \) kg (range) | 10.2 (6.2–22.5) | 10.8 (1.6–8.1) | .454 |
| CD34+, median, \( \times 10^9 \) kg (range) | 3.6 (1.6–8.2) | 3.7 (1.9–9.2) | .732 |

AML = acute myeloid leukemia, ATG = anti-thymocyte globulin, CR = complete remission, MDS = myelodysplastic syndrome, MNC = mononuclear cells, NHL = non-Hodgkin lymphoma, NR = nonremission, SCT = hematopoietic stem-cell transplantation, WBC = white blood cell.
3.3. cGVHD

Chronic GVHD was absent in 44 (64.7%) patients [31 (65%) in the ATG group vs 13 (46.4%) in the non-ATG group] (Table 2). The 3-year cumulative incidence of cGVHD was 52.3% (95% CI, 31.0%–69.6%) in the non-ATG group and 37.5% (95% CI, 17.8%–57.2%) in the ATG group (Fig. 2C, \( P < .001 \)). The overall cumulative incidence of extensive cGVHD alone was 19.8% (95% CI, 5.5–40.2) for the ATG group and 38.4% (95% CI, 19.6–57.1) for the non-ATG group after 3 years (Fig. 2D).

According to the NIH criteria, cGVHD severity was mild in 12 patients [17.6%; 3 (7.1%) in the ATG group vs 9 (30.0%) in the non-ATG group], moderate in 6 patients [8.8%; 3 (7.1%) in the ATG group vs 3 (10.0%) in the non-ATG group], and severe in 6 patients [8.8%; 2 (4.8%) in the ATG group vs 4 (13.3%) in the non-ATG group]. In multivariate analysis, the use of ATG was associated with reduced risk of chronic GVHD (hazard ratio, 3.2; 95% CI, 1.3–7.5; \( P = .002 \)) (Table 4). Nineteen patients with cGVHD were alive at the last follow-up.

Of the 41 patients in the ATG group who survived, 3 (7.7%) developed late aGVHD grade II. One patient had de novo late aGVHD (skin, day +310), one had persistent (liver) late aGVHD, and one had recurrent late aGVHD (lower gastrointestinal tract, day +103). No patients with late aGVHD died.

Within 3 years after MSD transplantation, 93.5% (38/40) patients stopped immunosuppressive medication in the ATG group, while 72.2% (13/18) discontinued in the non-ATG group.

3.4. Graft failure and engraftment

No graft failure occurred. One patient in the ATG group died of gastrointestinal hemorrhage before engraftment on day +14. The median time to leukocyte engraftment was 12 days (range, 9–19 days) in the ATG group and 13 days (range, 9–32 days) in the non-ATG group (Table 2). The median time to platelet engraftment in the ATG group was 14 days (range, 9–30 days) and 19 days (range, 9–38 days) in the non-ATG group (Table 2). One patient in the non-ATG group did not achieve platelet engraftment and died of disease relapse after 80 days of transplantation.

3.5. Toxicity, NRM, and relapse

Of the 72 patients, 6 (8.3%) died in remission due to transplant-related reason: 4 (9.5%) of 42 patients in the ATG group and 2 (6.7%) in the non-ATG group. The overall cumulative incidence of non-relapse mortality was 14% (95% CI, 9–21; Fig. 3A). Among these, five patients died of respiratory failure (3 in the ATG group and 1 in the non-ATG group), and 1 patient (ATG group) died of gastrointestinal hemorrhage, and no patients died of GVHD. No difference was observed in the 2-year cumulative incidence of NRM between the 2 groups [ATG 13.0% (95% CI, 0.0%–24.5%) vs non-ATG 8.3% (95% CI, 0.0%–18.3%); \( P = .640 \)] (Fig. 3A).

**Table 2**

| Variable | ATG group (n=42) | No-ATG group (n=30) | \( P \) |
|----------|------------------|---------------------|-------|
| Events (range) | | | |
| Graft failure, no. (%) | 0 (0) | 0 | |
| Prolonged isolated thrombocytopenia, no. (%) | 0 (0) | 1 | |
| Days to engraftment, median (range) | | | |
| Absolute neutrophil count \( \geq 0.5 \times 10^9/L \) | 12 (8–19) | 13 (9–32) | .475 |
| Platelet count \( \geq 20 \times 10^9/L \) | 14 (9–30) | 19 (9–38) | .026 |
| Infectious complication, no. (%) | | | |
| Cytomegalovirus reactivation, no. (%) | 11 (26.2) | 6 (20.0) | .587 |
| Epstein–Barr virus reactivation, no. (%) | 11 (26.2) | 2 (6.7) | .03 |
| Posttransplantation lymphoproliferative disorder, no. (%) | | | |
| Fungal infection, no. (%) | 0 (0) | 13 (43.3) | .001 |
| Overall grades of aGVHD, no. (%) | | | |
| 0 | 27 (65.9) | 20 (66.7) | |
| I | 2 (4.9) | 2 (6.7) | |
| II | 11 (26.8) | 6 (20.0) | |
| III | 1 (2.4) | 1 (3.3) | |
| IV | 0 (0) | 1 (3.3) | |
| II–IV | 12 (29.3) | 8 (26.7) | .931 |
| III–IV | 1 (2.4) | 2 (6.7) | .370 |
| Chronic GVHD | | | |
| Day of onset | 543 (270–957) | 423 (130–1008) | .103 |
| Severity according to revised Seattle criteria, no. (%) | | | |
| Limited | 4 (9.5) | 6 (20.0) | .008 |
| Extensive | 4 (9.5) | 10 (33.3) | |
| Severity according to NIH criteria, no. (%) | | | |
| Mild | 3 (7.1) | 9 (30.0) | .330 |
| Moderate | 3 (7.1) | 3 (10.0) | |
| Severe | 2 (4.8) | 4 (13.3) | |

ATG = Anti-thymocyte globulin, GVHD = graft-versus-host disease.

Chronic, limited, and extensive grades of GVHD were defined according to the Seattle criteria. Chronic, mild, moderate, and severe grades of GVHD were defined according to the NIH criteria.

---

**Table 2**

**Rates of engraftment, infection, aGVHD and cGVHD, and other complications after allogeneic PBSCT from HLA-identical sibling.**

| Variable | ATG group (n=42) | No-ATG group (n=30) | \( P \) |
|----------|------------------|---------------------|-------|
| Events (range) | | | |
| Graft failure, no. (%) | 0 (0) | 0 | |
| Prolonged isolated thrombocytopenia, no. (%) | 0 (0) | 1 | |
| Days to engraftment, median (range) | | | |
| Absolute neutrophil count \( \geq 0.5 \times 10^9/L \) | 12 (8–19) | 13 (9–32) | .475 |
| Platelet count \( \geq 20 \times 10^9/L \) | 14 (9–30) | 19 (9–38) | .026 |
| Infectious complication, no. (%) | | | |
| Cytomegalovirus reactivation, no. (%) | 11 (26.2) | 6 (20.0) | .587 |
| Epstein–Barr virus reactivation, no. (%) | 11 (26.2) | 2 (6.7) | .03 |
| Posttransplantation lymphoproliferative disorder, no. (%) | | | |
| Fungal infection, no. (%) | 0 (0) | 13 (43.3) | .001 |
| Overall grades of aGVHD, no. (%) | | | |
| 0 | 27 (65.9) | 20 (66.7) | |
| I | 2 (4.9) | 2 (6.7) | |
| II | 11 (26.8) | 6 (20.0) | |
| III | 1 (2.4) | 1 (3.3) | |
| IV | 0 (0) | 1 (3.3) | |
| II–IV | 12 (29.3) | 8 (26.7) | .931 |
| III–IV | 1 (2.4) | 2 (6.7) | .370 |
| Chronic GVHD | | | |
| Day of onset | 543 (270–957) | 423 (130–1008) | .103 |
| Severity according to revised Seattle criteria, no. (%) | | | |
| Limited | 4 (9.5) | 6 (20.0) | .008 |
| Extensive | 4 (9.5) | 10 (33.3) | |
| Severity according to NIH criteria, no. (%) | | | |
| Mild | 3 (7.1) | 9 (30.0) | .330 |
| Moderate | 3 (7.1) | 3 (10.0) | |
| Severe | 2 (4.8) | 4 (13.3) | |
Table 2 shows the incidence of viral infections (human Epstein–Barr virus, CMV, and disease) and fungal infections in the two groups. No post-transplantation lymphoproliferative disorder was observed (Table 2). Notably, patients receiving the ATG regimen had a higher incidence of viral reactivation compared with the non-ATG group. The difference was significant for the Epstein–Barr virus reactivation [11 (26.2%) of 42 in the ATG group vs 2 (6.7%) of 30 in the non-ATG group; \( P = .03 \)]. No significant difference was founded in the incidence of human CMV reactivation between the two groups [11 (26.2%) of 42 in the ATG group vs 6 (20.0%) of 30 in the non-ATG group; \( P = 0.587 \)]. Clinical Fungal infection [4 (9.5%) of 42 in the ATG group vs 13 (43.3%) of 30 in the non-ATG group; \( P < .01 \)] was significantly higher in the non-ATG group than in the ATG group.

Further, 16 patients undergoing MSD-PBSCT (22.2%) relapsed at 388 (93–966) days post transplantation [6 (14.3%) in the ATG group and 10 (33.3%) in the non-ATG group]. The 3-year cumulative incidence of relapse was not statistically different (\( P = .078 \)) in the two groups [23.1% (95% CI, 4.4%–38.1%) in the ATG group vs 36.5% (95% CI, 15.4%–36.5%) in the non-ATG group], Figure 3B. In multivariate analyses, high-risk disease, according to the disease risk index, was the factor most closely associated with relapse [hazard ratio, 192.0 (95% CI, 3.7–94.9), \( P = .009 \)]. Up to December 1, 2019, 15 relapsed patients died although they received salvage chemotherapy and donor lymphocyte infusion, one relapsed patient (ATG group) was alive in remission. Up to December 1, 2019, no patient had developed a secondary malignancy.

![Figure 2. Cumulative incidence of aGVHD and cGVHD after MSD-PBSCT with ATG combined with cyclosporine, mycophenolate, and short-term methotrexate as GvHD prophylaxis compared with the non -ATG group. ATG=antithymocyte globulin, GvHD = graft-versus-host disease.](image-url)
### 3.6. Survival

On the day of analysis, 51 (70.8%) patients were alive in CR (complete remission). The 3-year OS probability was 63.4% (95% CI, 51.6%–78.1%) for the whole study population: 71.0% (95% CI, 56.3%–89.4%) for the ATG group and 62.0% (95% CI, 46.5%–82.6%) for the non-ATG group (P = 0.262, Fig. 3C). The 3-year DFS probability was 63.0% (95% CI, 51.5–76.9) for the whole study population: 66.7% (95% CI, 51.4%–86.7%) for the ATG group and 58.4% (95% CI, 42.8%–79.7%) for the non-ATG group (P = 0.343, Fig. 3D). The 3-year GRFS probability was 54.1% (95% CI, 42.4%–69.1%) for the whole study population: 66.7% (95% CI, 51.4%–86.7%) for the ATG group and 40.0% (95% CI, 25.3%–63.4%) for the non-ATG group (P < .001, Fig. 3E). In univariate and multivariate analyses, the non-ATG group was a risk factor for GRFS (Tables 4 and 5).

### 3.7. Outcomes of the randomized first 60 patients by interim analysis

Using Gray’s test with competing risks, the cumulative incidence of aGVHD grades II–IV was 20.0% (95% CI, 7.9%–35.9%) in the ATG group and 26.7% (95% CI, 12.4%–43.3%) in the non-ATG group (P = .480). The cumulative incidence of grades III–IV was 0% in the ATG group and 6.8% (95% CI, 1.2%–19.5%) in the non-ATG group at day +100 (P = .150). Chronic GVHD developed in 2 (6.7%) patients in the ATG group and 14 (46.7%) patients in the non-ATG group (P < .001). The cumulative incidence of cGVHD was 44.5% (95% CI, 24.8%–66.0%) in the non-ATG group and 5.7% (95% CI, 0.3%–33.9%) in the ATG group after 2 years (P < .001). The 2-year OS probability was 69.3% (95% CI, 52.1%–92.1%) for the ATG group and 62.0% (95% CI, 46.5%–82.6%) for the non-ATG group (P = .382). The 2-year DFS probability was 69.5% (95% CI, 52.4%–92.1%) for the ATG group and 62.3% (95% CI, 46.9%–82.7%) for the non-ATG group (P = .526). The 2-year GRFS probability was 54.1% (95% CI, 42.4%–69.1%) for the whole study population: 69.5% (95% CI, 52.4%–92.1%) for the ATG group and 52.0% (95% CI, 36.6%–73.9%) for the non-ATG group (P = .073).

### 3.8. Immune reconstitution

14 patients in the ATG group and 13 patients in the no-ATG group were studied for immune reconstitution at all time points. On day +100, median CD3+, CD4+, CD8+, and CD56/CD16+ counts were 914 (290–250), 189 (63–488), 878 (250–1500), and 315 (111–546), respectively. There were no differences between the ATG and non-ATG group. There was no association between CD3+, CD4+, CD8+ or CD56+ cell counts at all time points and relapse, the occurrence of GVHD and CMV/EBV reactivation.

### 4. Discussion

The administration of a 5-mg/kg total dose of rATG (days –5 to –1) as GVHD prophylaxis in this study demonstrated the following:

1. Lower incidence of cGVHD in patients with rATG,
2. Improved GRFS rates in patients with rATG,
3. No effect of rATG on the incidence or severity of aGVHD, CMV reactivation, relapse, and NRM and,
4. Higher incidence of EBV reactivation, but no PTLD, in patients with rATG.

High cGVHD rates have been recognized as one of the major drawbacks of MSD-PBSCT. rATG has been used for in vivo T-cell depletion with the goal of improving transplant outcomes. In a meta-analysis of 6 randomized trials with 568 transplantation patients, the incidence of severe aGVHD (grades III–IV) and aGVHD (grades II–IV) were significantly reduced.

#### Table 4

Univariate analysis of transplant outcomes for the risk factors in all patients.

| Disease Risk Index | Non-ATG | ATG | Hazard Ratio (95% CI) | P value |
|-------------------|---------|-----|----------------------|---------|
| Advanced stage of disease | No ATG | ATG | HR (95% CI) | P value |
| Extensive | 0.8 (0.1–7.9) | 0.02 (0.0–0.2) | 0.001 | |
| Intermediate | 1.2 (0.1–8.2) | 0.01 (0.0–0.2) | 0.001 | |
| Low | 1.0 | 1.0 | 1.0 | 1.0 |

| Remission status | Non-ATG | ATG | Hazard Ratio (95% CI) | P value |
|------------------|---------|-----|----------------------|---------|
| Complete remission | 1.0 | 1.0 | 1.0 | 1.0 |

| Time from diagnosis to transpl | < 6 mo | > 6 mo | Hazard Ratio (95% CI) | P value |
|-----------------------------|-------|-------|----------------------|---------|
| Non-ATG | 1.2 (0.1–3.1) | 0.9 (0.0–2.0) | 0.737 | |
(from 18% to 10% for severe aGVHD and from 36% to 19% for aGVHD) with the addition of high doses of ATG. However, this benefit did not result in improved survival. One randomized study using 10 mg/kg of rabbit ATLG in sibling myeloablative transplantation showed decreased cGVHD incidence. The incidence of cGVHD and extensive cGVHD were significantly reduced (from 68.7% to 32.2% for cGVHD and from 33.3% to 6.0% for extensive cGVHD) with the addition of ATLG. Despite relatively low cGVHD incidences in these patients, OS and progression-free survival did not improve in both study groups. Therefore, the optimal ATG regimen that achieves a balance between immunosuppressive activity and minimum toxicity remains to be elucidated. In this study, the cumulative incidence of cGVHD was 37.3% in the ATG group and 52.1% in the non-ATG group after 3 years. The overall cumulative incidence of extensive cGVHD alone was 19.5% for the ATG group and 38.4% for the non-ATG group after 3 years. The significantly lower incidence of cGVHD in the ATG group resulted in a significantly higher rate of survival free of cGVHD and relapse among patients who received ATG compared with those who did not receive ATG (66.7% vs 40.0%), as the incidence of relapse was not statistically different. In the present study, the rates of GRFS were significantly higher in the ATG group than in the non-ATG group. Thus, 5-mg/kg of rATG on days −5 to −4 may lead to the reduction of the incidence of severe or extensive cGVHD and improve survival.

rATG targets alloreactive T cells at the expense of potentially increasing the risk of infections after transplantation and delayed immune reconstitution. rATG administration persists for long periods in vivo and causes relapse and infection. Experimental studies have showed that rATG induced apoptosis toward different hematologic malignancies, antibody-dependent cell-mediated cytotoxicity, and complement-dependent cytotoxicity. Socie et al. found that relapse was not related with Thymoglobulin doses less than 6 mg/kg, which was consistent with the finding of the present study. This study confirmed that the 3-year cumulative incidence of relapse was not statistically different in the two groups. No difference was observed in the cumulative incidence of NRM between the ATG and non-ATG groups (13.0% vs 8.5%). rATG is considered a risk factor for EBV reactivation and posttransplant lymphoproliferative disorder. Notably, patients receiving the ATG regimen had a
greater incidence of Epstein–Barr virus reactivations compared with those in the non-ATG group, but not CMV reactivation. No posttransplantation lymphoproliferative disorder was observed in this study. Fungal infection (9.5% vs 43.3%) was significantly higher in the non-ATG group than in the ATG group. The development of cGVHD (7 cGVHD in 13 patients with fungal infection) and high dosage of corticosteroids were the major reason for the high incidence of fungal infection in the non-ATG group.

5. Conclusions

In summary, this study showed that the incorporation of rATG (at 5-mg/kg of the total dose administered from days 5 to 4) in adult patients undergoing MSD-PBSCT resulted in a significantly lower rate of cGVHD, and improved GRFS, compared with those in the non-ATG group. The rates of relapse were similar in the two groups. Whether 5 mg/kg of rATG for MSD-PBSCT patients is the optimal dose or not need more evidence. Novel approaches of optimizing ATG dosage based on pharmacokinetic analysis, should be explored further.\[32–34]\n
Acknowledgments

We thank Shanmei Liao for supporting us for statistical analyses.

Author contributions

All authors read and approved the final manuscript.
Data Collection: WH, SW
Data Interpretation: FL, XG
Funds Collection: DL
LD recruited patients, collected data, did the data analysis and interpretation of the data and drafted the manuscript.
Literature Search: LW, YL

References

[1] Bonifazi F, Solano C, Wolschke C, et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematol 2019;6:e89–99.
[2] Nishihori T, Al-Kadhimi Z, Hamadani M, et al. Anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy 2016;8:435–47.
[3] Bosch M, Dhadda M, Hoegh-Petersen M, et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012;14:1258–75.

Table 5

|                      | Univariate | Multivariate |
|----------------------|------------|-------------|
|                      | HR 95% CI  | P        | HR 95% CI  | P        |
| GRFS                 |            |          |            |          |
| Group                |            |          |            |          |
| No ATG               | 1.0        |          | 1.0        |          |
| ATG                  | 0.4        | 0.2–0.9  | <.001      | 0.1      | 0.0–0.5  | .002 |
| OS                   |            |          |            |          |
| Group                |            |          |            |          |
| No ATG               | 1.0        |          | 1.0        |          |
| ATG                  | 0.6        | 0.3–1.4  | .262       | 0.2      | 0.1–0.9  | .032 |
| DFS                  |            |          |            |          |
| Group                |            |          |            |          |
| No ATG               | 1.0        |          | 1.0        |          |
| ATG                  | 0.7        | 0.3–1.5  | .334       | 0.2      | 0.1–0.9  | .031 |
| Chronic GVHD         |            |          |            |          |
| Group                |            |          |            |          |
| No ATG               | 0.3        | 0.1–0.7  | <.001      | 0.1      | 0.0–0.4  | .002 |
| Extensive chronic GVH|            |          |            |          |
| Group                |            |          |            |          |
| No ATG               | 1.0        |          | 1.0        |          |
| ATG                  | 0.2        | 0.1–0.6  | .060       | 0.0      | 0.0–0.6  | .028 |

95% CI = cumulative incidence 95% CI, ATG = anti-thymocyte globulin, DFS = disease-free survival, GRFS = severe GVHD-free, relapse-free survival, GVHD = graft-versus-host disease, OS = overall survival.
Chronic, limited, and extensive grades of GVHD were defined according to the Seattle criteria. Chronic, mild, moderate, and severe grades of GVHD were defined according the NIH criteria.
*P means *P value.
[4] Bonfazi F, Bandini G, Arpinati M, et al. Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSCT transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis. Bone Marrow Transplant 2012;47:1105–11.

[5] Admiraal R, Lindemans CA, van Kesteren C, et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood 2016;128:2734–41.

[6] Sahel I, Batsis I, Boussou Z, et al. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies. Clin Lymphoma Myeloma Leuk 2017;17:658–66.

[7] Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol 2015;2:e194–203.

[8] Locatelli F, Bernardo ME, Bertaino A, et al. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:1126–36.

[9] Socie G, Schmoor C, Bettega WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011;117:6375–82.

[10] Soiffer RJ, Kim HT, McGurik J, et al. Prospective, randomized, double-blind, phase 1b clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing hla-matched unrelated haematopoietic stem cell transplantation. J Clin Oncol 2017;35:4003–11.

[11] Kroger N, Solano C, Wolschke C, et al. Anti lymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 2016;374:43–53.

[12] Li HH, Li F, Gao C, et al. Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSC from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies. Br J Haematol 2017;176:92–100.

[13] Dou L, Hou C, Ma C, et al. Reduced risk of chronic GVHD by low dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Ann Hemtol 2020;99:167–79.

[14] Zhao XF, Mao XF, Wan DM, et al. Modified busulphan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematological malignancies. Transplant Proc 2014;46:1531–5.

[15] Lee SE, Cho BS, Kim JH, et al. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplant 2013;48:587–92.

[16] Rihn C, Cilley J, Naik P, et al. Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation. Haematologica 2004;89:763–4.

[17] Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009;114:702–8.

[18] Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a center for international blood and marrow transplant research analysis. Blood 2011;117:6714–20.

[19] Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014;123:3664–71.

[20] Sandmaier BM, Kornblit B, Storer BE, et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol 2016;3:e409–18.

[21] Blazar BR, Murphy WJ, Abdi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012;12:443–58.

[22] Giebel S, Labopin M, Czerw T, et al. Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer 2019;106:212–9.

[23] Retiere C, Willem C, Guillaume T, et al. Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Oncotarget 2018;9:11451–64.

[24] Theurich S, Fischmann H, Shimabukuro-Vornhagen A, et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev 2012;CD009159.

[25] Gagelmann N, Ayuk F, Wolschke C, et al. Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis. Biol Blood Marrow Transplant 2017;23:2184–91.

[26] Storek J, Mohny M, Boeens JJ. Rabbit anti-T-cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015;21:959–70.

[27] Tandara A, Covut F, Cooper B, et al. Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation. Leuk Lymphoma 2018;59:1644–51.

[28] Bonifazi F, Olivieri J, Sessa M, et al. Low dose anti-T lymphoglobulin vs prophylaxis for graft-versus-host disease in unrelated donor transplantsations for acute leukemias and myelodysplastic syndromes. Biol Blood Marrow Transplant 2018;24:2450–8.

[29] Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;17:2844–53.

[30] Czerw T, Labopin M, Giebel S, et al. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Cancer 2018;124:2523–33.

[31] Devillier R, Labopin M, Chevallier P, et al. Impact of anti-thymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donors for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. Bone Marrow Transplant 2018;53:431–7.

[32] Salomon RM, Ripley R, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003;54:96–104.

[33] Sharf R, Sarhan M, Dileone RJ. Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell. Biol Psychiatry 2008;64:175–83.

[34] Valimaki M, Pelkonen R, Härkönen M, et al. Hormonal changes in noncirrhotic male alcoholics during ethanol withdrawal. Alcohol Alcohol 1984;19:235–42.